120 results
6-K
EX-99.1
GLPG
Galapagos NV
30 May 24
Current report (foreign)
4:44pm
manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy.
About Galapagos
We
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
access to potentially life-saving CAR-T treatments
Important milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials … quality control testing and release strategy.
About Galapagos
We are a biotechnology company with operations in Europe and the U.S. dedicated
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
development
We will continue to evaluate business development opportunities that fit our strategy to accelerate and expand our pipeline of potential … regulatory outlook, statements regarding the amount and timing of potential future milestones, and other payments, statements regarding our R&D plans, strategy
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
) and a proprietary quality control testing and release strategy.
About the ATALANTA-1 study (EudraCT 2021-003272-13)
ATALANTA-1 is an ongoing Phase 1/2 … studies and other analyses related to Galapagos’ CD19 CAR-T program, statements related to Galapagos’ plans, expectations and strategy with respect
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Report 2023
Our Business Overview of our company, our strategy, and 2023 key achievements Pioneering science to transform patient outcomes
OUR BUSINESS … and conditions contained in this annual report, including statements regarding our future results of operations and financial positions, business strategy
6-K
EX-99.15
hbvy6d
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
utaa1em73z5uv alai
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
6-K
EX-99.1
jg8i hv47t
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
oen6m3ybw niw1fujv0
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
8fuai8 i2i32
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
skjg i4pk
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
7yftq6jf
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
akdkjuq1u 8c3mx
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
fyhr n2rik
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
bpztm
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
wekagzbgxhxu386cqn
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
i1wac8tq95ztc1
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
pgb7n3j ppkv4gz0l9
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
9u4a1q 1phrnr
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm